Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
The diagnosis and management of pre-invasive breast disease: promise of new technologies in understanding pre-invasive breast lesions.
PMID 14580250 · PMC314415 · Breast cancer research : BCR · 2003 · 8 claims · 8 setups
ADH and ductal carcinoma in situ (DCIS) are precursor lesions molecularly similar to adjacent invasive breast cancer
-
Has reproduction · 85
The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprograming in estrogen receptor-positive breast cancer.
PMID 33772001 · PMC7998036 · Nature communications · 2021 · 8 claims · 8 setups
AAMDC is an amplified/overexpressed oncogene in a subgroup of ER-positive breast cancers (IntClust2) associated with poor prognosis
-
Full-text index only
A candidate metastasis-associated DNA marker for ductal mammary carcinoma.
PMID 12631399 · PMC154149 · Breast cancer research : BCR · 2003 · 8 claims · 8 setups
RDA comparing normal and metastatic ductal breast carcinoma cell DNA identified 10 unique metastasis-associated DNA sequences (MADS) apparently lost in metastatic cells
-
Full-text index only
Surface-enhanced laser desorption/ionization time-of-flight proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression.
PMID 18510725 · PMC2481497 · Breast cancer research : BCR · 2008 · 7 claims · 7 setups
Unsupervised hierarchical clustering of 130 SELDI-TOF peaks yielded six peak clusters and five distinct groups of breast cancer patients.
-
Full-text index only
PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.
PMID 18371219 · PMC2397526 · Breast cancer research : BCR · 2008 · 7 claims · 4 setups
PIK3CA mutations are not associated with altered sensitivity to preoperative anthracycline-based or taxane-based chemotherapy in ER-positive and ER-negative breast tumors
-
Full-text index only
Complex landscapes of somatic rearrangement in human breast cancer genomes.
PMID 20033038 · PMC3398135 · Nature · 2009 · 8 claims · 6 setups
There are more somatic rearrangements in some breast cancers than previously appreciated by cytogenetic methods.
-
Full-text index only
The use of laser capture microscopy in proteomics research--a review.
PMID 15502248 · PMC3839334 · Disease markers · 2004 · 8 claims · 8 setups
LCM allows purification of specific, histologically defined cell populations from heterogeneous tissue for downstream proteomic analysis
-
Full-text index only
25th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 10-14 December 2002 Update on preclinical and translational research.
PMID 12631391 · PMC154153 · Breast cancer research : BCR · 2003 · 8 claims · 8 setups
Growth factor signalling (EGF/HER-2/MAPK, AKT) phosphorylates the oestrogen receptor and drives development of endocrine-resistant breast cancer
-
Full-text index only
The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients.
PMID 19756916 · PMC2778706 · Targeted oncology · 2009 · 8 claims · 5 setups
Genomic/gene expression profiling alone is insufficient to identify tumors with molecular pathway changes predictive of treatment outcome; protein-level functional assessment (activation states, PTMs, interactions) is also required
-
Full-text index only
A sequence-based survey of the complex structural organization of tumor genomes.
PMID 18364049 · PMC2397511 · Genome biology · 2008 · 8 claims · 6 setups
End sequencing profiling (ESP) can identify all classes of genome rearrangements in tumor genomes by paired-end sequencing of BAC clones
-
Full-text index only
Pharmacogenomic biomarkers.
PMID 12364812 · PMC3850811 · Disease markers · 2002 · 8 claims · 8 setups
Development of a pharmacogenomic biomarker requires sequential steps: laboratory identification, retrospective confirmation in clinical samples, prospective clinical trial validation, and regulatory approval before patient stratification.